SYNBIOTIC SE Expands by Acquiring Ilesol Pharmaceuticals

SYNBIOTIC SE, a German industrial hemp and cannabis group, has announced the acquisition of Ilesol Pharmaceuticals, a company based in Varaždin, Croatia. This strategic move includes the takeover of Ilesol's 3,400 m2 production facility that specializes in the production of cannabinoid extracts and isolates. Alongside its technical capabilities, Ilesol also brings a range of CBD natural cosmetics to SYNBIOTIC's existing portfolio.

With this acquisition, SYNBIOTIC aims to fortify its position in the European market, asserting control over the production of 'Made in EU' CBD isolates. According to SYNBIOTIC's Managing Director, Daniel Kruse, this development secures a significant competitive advantage by integrating crucial processes into their supply chain. The acquisition not only supports the internal production demands but also bolsters the group's potential in a rapidly growing market for hemp extracts and CBD isolates, especially within the cosmetics industry.

Furthermore, this acquisition follows closely the acquisition of Bushdoctor, marking the second significant takeover by SYNBIOTIC in a span of four months and extending its operational reach to Austria and Croatia. This expansion enhances SYNBIOTIC's distribution capabilities and complements its existing brands and products, effectively strengthening its market position throughout Europe and potentially attracting more strategic investments from beyond the continent.